Waters Corporation: Regulatory & Application Growth in PFAS Testing Is  Critical Growth Enabler! 

Waters Corporation reported strong fourth quarter and full-year financial results for 2024, reflecting a positive growth trajectory within the life sciences sector. The company achieved a 6.4% reported sales growth in the fourth quarter, 8% on a constant currency basis, and attained high single-digit growth in instruments and recurring revenues. Earnings per share (EPS) showcased robust growth with a 13% increase to $4.10 on a non GAAP basis, showcasing the firm’s resilience amidst challenging economic conditions. This performance was supported by broad-based regional growth across Europe, Asia, and the Americas, with standout performances in the pharmaceutical and academic markets.